6/18
08:00 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
6/17
04:10 pm
kros
Keros Therapeutics Announces Leadership Updates [Yahoo! Finance]
Low
Report
Keros Therapeutics Announces Leadership Updates [Yahoo! Finance]
6/17
04:01 pm
kros
Keros Therapeutics Announces Leadership Updates
Low
Report
Keros Therapeutics Announces Leadership Updates
6/17
06:13 am
kros
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association [Yahoo! Finance]
Medium
Report
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association [Yahoo! Finance]
6/17
06:00 am
kros
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
Medium
Report
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
6/4
08:09 am
kros
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast [Yahoo! Finance]
Low
Report
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast [Yahoo! Finance]
6/4
08:00 am
kros
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
Low
Report
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
6/3
08:00 am
kros
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Medium
Report
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
5/28
04:12 pm
kros
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors [Yahoo! Finance]
Medium
Report
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors [Yahoo! Finance]
5/28
04:01 pm
kros
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
Medium
Report
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
5/14
10:06 am
kros
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association [Yahoo! Finance]
Low
Report
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association [Yahoo! Finance]
5/14
10:00 am
kros
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
Medium
Report
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
5/9
08:17 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
5/8
08:21 am
kros
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results [Yahoo! Finance]
5/8
08:00 am
kros
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Low
Report
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
4/15
09:14 am
kros
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%? [Yahoo! Finance]
Low
Report
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%? [Yahoo! Finance]
3/27
01:09 pm
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $105.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $105.00 price target on the stock.